‘This could be the next $1 billion drug’

Drugmakers have had to confront patient distrust of the medical system and the system’s marginalization of sickle cell patients, reports Marketwatch. Read the full article, featuring interview with Modus Therapeutics Chief Executive Ellen Donnelly.